As pro‐tumorigenic TGF‐β and AKT/mTOR signaling pathways were driven by CLTC in osteosarcoma, our study also encourages the development of TGF‐β inhibitors and AKT inhibitors for osteosarcoma therapy. The gene discussed is MTOR; the disease is osteosarcoma.